Cargando…
Delivering bioactive cyclic peptides that target Hsp90 as prodrugs
The most challenging issue facing peptide drug development is producing a molecule with optimal physical properties while maintaining target binding affinity. Masking peptides with protecting groups that can be removed inside the cell, produces a cell-permeable peptide, which theoretically can maint...
Autores principales: | Huo, Yuantao, Buckton, Laura K., Bennett, Jack L., Smith, Eloise C., Byrne, Frances L., Hoehn, Kyle L., Rahimi, Marwa N., McAlpine, Shelli R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407599/ https://www.ncbi.nlm.nih.gov/pubmed/30822267 http://dx.doi.org/10.1080/14756366.2019.1580276 |
Ejemplares similares
-
Synthesis and Structure–Activity Relationships
of Inhibitors That Target the C-Terminal MEEVD on Heat Shock
Protein 90
por: Rahimi, Marwa N., et al.
Publicado: (2017) -
Role of the Hsp90 cochaperone, FKBPL, in oestrogen receptor signalling and breast cancer growth and survival
por: McKeen, H, et al.
Publicado: (2008) -
Solid Phase versus Solution Phase Synthesis of Heterocyclic Macrocycles
por: Kim, Seong Jong, et al.
Publicado: (2013) -
Inhibitors of HSP90 in melanoma
por: Mielczarek-Lewandowska, Aleksandra, et al.
Publicado: (2019) -
Phase I Evaluation of STA-1474, a Prodrug of the Novel HSP90 Inhibitor Ganetespib, in Dogs with Spontaneous Cancer
por: London, Cheryl A., et al.
Publicado: (2011)